drugset / Trial / NCT04880876
A Study Evaluating Oral Eluxadoline Administered to Pediatric Participants With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Non-randomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the long-term safety of oral Eluxadoline administered to pediatric participants with IBS-D who have completed study intervention in the Phase 2 study 3030-202-002 or the Phase 3 study 3030-303-002.
Timeline
- Start
- 2021-08-13
- Primary completion
- 2032-12
- Completion
- 2032-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eluxadoline | Small molecule | 25 mg | Oral |
| Subject | Eluxadoline | Small molecule | 100 mg | Oral |